Clinical data | |
---|---|
Other names | ZK-115194; Cycloestradiol; 14α,17α-Ethano-17β-estradiol; 14α,17α-Ethanoestra-1,3,5(10)-triene-3,17β-diol; 14,21-Cyclo-19-norpregna-1,3,5(10)-triene-3,17α-diol |
Routes of administration | By mouth[1] |
Drug class | Estrogen |
Pharmacokinetic data | |
Bioavailability | 33 ± 19%[1] |
Elimination half-life | 28.7 hours[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H26O2 |
Molar mass | 298.426 g·mol−1 |
3D model (JSmol) | |
| |
|
Cyclodiol (developmental code name ZK-115194; also known as 14α,17α-ethano-17β-estradiol) is a synthetic estrogen which was studied in the 1990s and was never marketed.[2][1][3] It is a derivative of estradiol with a bridge between the C14α and C17α positions.[2][1][3][4] Cyclodiol has 100% of the relative binding affinity of estradiol for the human ERα and similar transactivational capacity as estradiol at the receptor.[2] It has comparable potency to estradiol when administered by subcutaneous injection.[2] The drug shows genotoxicity similarly to estradiol.[2][4] Cyclodiol showed an absolute bioavailability of 33 ± 19% and an elimination half-life of 28.7 hours in pharmacokinetic studies in women.[1]